Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of One Dose of OVX836 Influenza Vaccine 480μg, After Intramuscular Administration in Healthy Subjects Aged 18-59 Years

NCT05569239 is registered in ClinicalTrials.gov with Osivax as lead sponsor.

NCT NCT05569239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05569239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of One Dose of OVX836 Influenza Vaccine 480μg, After Intramuscular Administration in Healthy Subjects Aged 18-59 Years
Lead sponsor
Osivax
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 8, 2025
Completion date
May 29, 2026
Enrollment
2,850 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

influenza